leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma says clinical trials demonstrate the effectiveness of SHIR line of CBD skincare products

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application

InnoCan Pharma -
The SHIR facial serum contains 300 milligrams of CBD

Innocan Pharma Corporation (CSE:INNO) said Tuesday that clinical studies have demonstrated the effectiveness of the firm’s SHIR CBD facial serum on skin hydration.

The study looked at the impact of SHIR, which contains 300 milligrams of CBD, on hydration levels by measuring the skin capacitance periodically up to 24 hours after the serum was applied.

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application, according to a release from Innocan. In addition, the serum was well tolerated with no uncomfortable symptoms reported by participants.

READ: Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

All of the SHIR Derma Cosmetic products tested to date have demonstrated to be non-irritating in clinical testing, according to Israel-based Innocan.

CEO Iris Bincovich told investors that the results demonstrate the efficacy of the product.

"Hydrating the skin is one of the most crucial measures to keep the skin healthy, young and also to eliminate wrinkles,” Bincovich said in a statement.

“The amazing results of the new clinical studies are in addition to Innocan's research and development efforts to bring to market, a trustworthy product that will set a new industry standard.”

SHIR skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: InnoCan Pharma

Price: 0.175 CAD

CSE:INNO
Market: CSE
Market Cap: $30.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma teams up with Endless Sky to manufacturer and distribute its...

Innocan Pharma Corporation (CSE:INNO) CEO Iris Bincovich and Endless Sky CEO Travis George tells Proactive the two have signed a manufacturing and distribution agreement. Bincovich says Endless Sky will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its Health...

on 18/8/20

2 min read